Encyclopedia of Signaling Molecules

2012 Edition
| Editors: Sangdun Choi


  • Miles D. HouslayEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-1-4419-0461-4_336


Historical Background

Cyclic 3’5’ adenosine monophosphate (cAMP) is a key second messenger that is responsible for regulating many pivotal signaling processes in all mammalian cell types (Tasken and Aandahl 2004). It influences cell growth, differentiation, shape, and movement as well as processes such a cardiac contraction, metabolism, water retention, learning, and memory. Most intriguingly, however, cAMP can selectively regulate a variety of very different processes in any one particular cell type. Indeed, uncovering the molecular mechanisms that allow cAMP to selectively regulate disparate processes within a single cell has provided a major challenge. Only very recently has the means whereby cAMP signaling is compartmentalized in cells begun to be understood (Tasken and Aandahl 2004; Baillie et al. 2005; Willoughby and Cooper 2007). One key requirement is for spatially discrete signaling complexes to be assembled...

This is a preview of subscription content, log in to check access.


  1. Baillie GS, Scott JD, Houslay MD. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett. 2005;579:3264–70.PubMedGoogle Scholar
  2. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481–511.PubMedGoogle Scholar
  3. Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci. 2010;35:91–100.PubMedGoogle Scholar
  4. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 2003;370:1–18.PubMedGoogle Scholar
  5. Houslay MD, Adams DR. Putting the lid on phosphodiesterase 4. Nat Biotechnol. 2010;28:38–40.PubMedGoogle Scholar
  6. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10:1503–19.PubMedGoogle Scholar
  7. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des. 2010;16:1114–25.PubMedGoogle Scholar
  8. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109:366–98.PubMedGoogle Scholar
  9. Murdoch H, Vadrevu S, Prinz A, Dunlop A, Klussmann E, Bolger GB, Norman JC, Houslay MD. LIS1/cAMP phosphodiesterase-4 (PDE4) interaction and their role in cytoplasmic dynein function. J Cell Sci. 2011;124:2253–66.PubMedGoogle Scholar
  10. Tasken K, Aandahl ME. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 2004;84:137–67.PubMedGoogle Scholar
  11. Willoughby D, Cooper DM. Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev. 2007;87:965–1010.PubMedGoogle Scholar
  12. Zaccolo M. cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br J Pharmacol. 2009;158:50–60.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Molecular Pharmacology Group, Institute of Neuroscience and Psychology, CMVLSUniversity of GlasgowGlasgowUK